Percheron Therapeutics Limited has released a press release.
ATL1102 shows significant improvement vs external control
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- US FDA Grants RPDD to ATL1102 for the treatment of DMD
- Antisense to present new data at WMS Virtual Congress 2020
- ANP Submits EU Orphan Drug application for ATL1102 in DMD
- ANP Submits US Orphan Drug application for ATL1102 in DMD
- EMA DMD Scientific Advice and Regulatory Process Update
Later from Percheron Therapeutics
- Pause in Trading
- ANP receives US FDA ODD for ATL1102 in DMD
- ANP to apply for dual listing on Frankfurt Stock Exchange
- ANP raises A$7.3 million from Oversubscribed Placement
- Receipt of R&D Tax Incentive payment
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics